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Summary
 
The role of peroxynitrite in hypoxia–reoxygenation-induced coronary vasospasm was investi-
gated in isolated bovine coronary arteries. Hypoxia–reoxygenation selectively blunted prosta-
 
cyclin (PGI
 
2
 
)-dependent vasorelaxation and elicited a sustained vasoconstriction that was
blocked by a cyclooxygenase inhibitor, indomethacin, and SQ29548, a thromboxane (Tx)A
 
2
 
/
prostaglandin H
 
2
 
 receptor antagonist, but not by CGS13080, a TxA
 
2
 
 synthase blocker. The in-
activation of PGI
 
2
 
 synthase, as evidenced by suppressed 6-keto-PGF
 
1
 
a
 
 release and a decreased
conversion of 
 
14
 
C-prostaglandin H
 
2
 
 into 6-keto-PGF
 
1
 
a
 
, was paralleled by an increased nitration
in both vascular endothelium and smooth muscle of hypoxia–reoxygenation-exposed vessels.
The administration of the nitric oxide (NO) synthase inhibitors as well as polyethylene-glyco-
lated superoxide dismutase abolished the vasospasm by preventing the inactivation and nitra-
 
tion of PGI
 
2
 
 synthase, suggesting that peroxynitrite was implicated. Moreover, concomitant
administration to the organ baths of the two precursors of peroxynitrite, superoxide, and NO
mimicked the effects of hypoxia–reoxygenation, although none of them were effective when
given separately. We conclude that hypoxia–reoxygenation elicits the formation of superoxide,
which causes loss of the vasodilatory action of NO and at the same time yields peroxynitrite.
Subsequently, peroxynitrite nitrates and inactivates PGI
 
2
 
 synthase, leaving unmetabolized pros-
taglandin H
 
2
 
, which causes vasospasm, platelet aggregation, and thrombus formation via the
TxA
 
2
 
/prostaglandin H
 
2
 
 receptor.
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2
 
/
prostaglandin H
 
2
 
 receptor
 
U
 
nder physiological conditions, the endothelium pro-
vides vasodilatory and antiaggregatory properties to the
cardiovascular system and also prevents growth of the under-
lying vascular smooth muscle cells by releasing nitric oxide
(NO), endothelium-derived hyperpolarizing factor, and
prostacyclin (PGI
 
2
 
) (1–3). Each of these mediators acts by a
different mechanism, NO by the stimulation of guanylyl cy-
clase (2) and PGI
 
2
 
 by activating adenylyl cyclase, so that these
mediators can act synergistically and also serve as backup
systems for each other (1–3). It was interesting to study this
interdependence after a selective inhibition of PGI
 
2
 
 syn-
thase by peroxynitrite had been described (4). As peroxyni-
trite is generated in vivo by a rapid combination of NO
 
and superoxide radicals (O
 
2
 
.
 
2
 
) (5, 6), it seemed that O
 
2
 
.
 
2
 
not only can neutralize NO but subsequently, through its
product peroxynitrite, could suppress PGI
 
2
 
 formation. The
underlying mechanism for PGI
 
2
 
 synthase blockade has been
suggested as the nitration of a tyrosine residue at the active
site through a reaction catalyzed by the ferric iron of this
heme-thiolate (P450) protein (7). In spite of the cellular anti-
oxidant potential, peroxynitrite causes PGI
 
2
 
 synthase nitration
in whole cells (8) as well as in intact coronary arteries (9).
Endothelial dysfunction (impaired vasorelaxation and/or
increased vasoconstriction) is an important early-recurring
phenomenon in virtually all forms of ischemia/reperfusion
diseases, including a variety of shock states (10). This dys-
function appears to be triggered simultaneously with the
endothelial generation of O
 
2
 
.
 
2
 
. Therefore, the formation of
peroxynitrite during hypoxia–reoxygenation is likely be-
cause of a simultaneous generation of NO and O
 
2
 
.
 
2
 
 (11).
In this study, we investigated a role of peroxynitrite in hy-
poxia–reoxygenation-induced coronary vasospasm by mon-
itoring the pattern of angiotensin II–triggered vasoconstric-
tion/vasorelaxation, PGI
 
2
 
 release, and the nitration of PGI
 
2
 
synthase. Our results suggest that hypoxia–reoxygenation
elicits peroxynitrite formation, leading to a subsequent ni-
tration and inhibition of PGI
 
2
 
 synthase. Most importantly,
the unmetabolized PGH
 
2
 
 triggers vasospasm by acting upon
the thromboxane (Tx)A
 
2
 
/PGH
 
2 
 
receptor before being con-
verted to PGE
 
2
 
. 
136
 
Hypoxia–Reoxygenation Causes Nitration of Prostacyclin Synthase
 
Materials and Methods
 
Materials.
 
All chemicals, if not indicated otherwise, were ob-
tained from the same sources as previously described (9). N
 
v
 
-mono-
methyl-
 
l
 
-arginine (L-NMMA), N
 
v
 
-nitro-
 
l
 
-arginine methyl ester
(L-NAME), and diethylamine NONoate (DEA-NO) were ob-
tained from Cayman SPI. Polyethylene-glycolated superoxide
dismutase (PEG-SOD) was obtained from Sigma Chemical Co.
 
14
 
C-PGH
 
2
 
 was prepared from 
 
14
 
C-arachidonic acid as previously
described (4, 7). Rabbit anti–PGI
 
2
 
 synthase antisera were pro-
duced in this laboratory as previously described (12).
 
Experimental Protocol.
 
As previously described (9), bovine
coronary arteries (BCA) of the left ventricle were isolated and re-
suspended in a tissue bath with 15 ml of Krebs buffer, gassed with
95% O
 
2
 
/5% CO
 
2
 
 (37
 
8
 
C; pH 7.4), and attached to a force–dis-
placement TFT6V5 transducer coupled to a polygraph for the
measurement of isometric tension. Passive tension was adjusted
to 
 
z
 
1 g over a 30-min equilibrating period, and then coronary
arteries were preconstricted by addition of the Tx mimetic
U46619 (0.001–0.01 
 
m
 
mol/liter). The vasorelaxation after ace-
tylcholine (0.01–1 
 
m
 
mol/liter) was used to demonstrate the pres-
ence of endothelium-dependent relaxation. Throughout the ex-
periment, care was taken to avoid any injury to the endothelium.
Experiments were started by obtaining from each spiral a refer-
ence response of vasoconstriction–relaxation with angiotensin II
(50 nM) for 30 min. After removal of the agonist from the cham-
bers and return of tone to basal levels, the oxygen tension was
then reduced abruptly from 95% O
 
2 
 
/5% CO
 
2
 
 to 95% N
 
2 
 
/5%
CO
 
2
 
 (hypoxia, PO
 
2 
 
5 
 
10 
 
6
 
 3 mmHg) and was maintained for
10-, 30-, or 40-min hypoxia. After this phase of hypoxia, 95%
O
 
2
 
/5% CO
 
2
 
 was resumed (reoxygenation), and the tension was
allowed to stabilize for 40 min before addition of agonists. If re-
quired, pharmacological agents were added in the organ chamber
40 min before hypoxia and kept during hypoxia–reoxygenation
and the second stimulation with the agonists. Tissues were kept
for immunohistochemistry or immunoprecipitation and Western
blots. The media from the first and second stimulations with an-
giotensin II were collected and stored at 
 
2
 
20
 
8
 
C for prostanoid
analysis, as previously described (9), using ELISA kits according
to the manufacturer’s instructions.
 
Activity Assay of PGI
 
2
 
 Synthase.
 
BCA spirals with or without
hypoxia–reoxygenation were incubated with 100 
 
m
 
M 
 
14
 
C-PGH
 
2
 
for 3 min as previously described (4, 7, 9). The reaction was
stopped by acidification with 1 N HCl to pH 3.5. The incubation
media were extracted with ethyl acetate (3 vol). After centrifuga-
tion, the organic phases were evaporated to dryness under nitro-
gen. Samples were then resuspended in 60 
 
m
 
l of ethyl acetate and
subsequently separated by TLC (ethyl acetate/water/iso-octane/
acetic acid, 90:100:50:20). Prostanoids were quantified with a Phos-
phorImager system (ImageQuant; Molecular Dynamics).
 
Immunohistochemistry, Immunoprecipitation, and Western Blots.
 
Immunohistochemistry, immunoprecipitation, and Western blots
of 3-nitrotyrosine–containing protein in hypoxia–reoxygenation-
treated BCA were performed as previously described (9).
 
Results and Discussion
 
In BCA, angiotensin II elicited a biphasic response consist-
ing of a primary vasoconstriction that was selectively blocked
by losartan, a selective angiotensin 1 receptor blocker, and a
secondary vasorelaxation that was mainly PGI
 
2
 
 dependent (9).
Abrupt decrease of oxygen tension from 95% O
 
2
 
/5%
CO
 
2
 
 to 95% N
 
2 
 
/5% CO
 
2
 
 caused a slight decrease in ten-
sion after a transient rise. Reoxygenation (from 95% N
 
2 
 
/
5% CO
 
2
 
 to 95% O
 
2 
 
/5% CO
 
2
 
) did not alter the tension of
unstimulated arteries. Although hypoxia–reoxygenation did
not affect the initial constriction of angiotensin II, it selec-
tively blunted the angiotensin II–triggered relaxation phase
after 30 min of hypoxia. Along with this suppression of the
relaxation phase, a second constriction phase developed in
parallel, with a decrease of 6-keto-PGF
 
1
 
a
 
 (Fig. 1 A) that
closely resembled the pattern seen previously after peroxy-
nitrite pretreatment (9).
Both the COX (cyclo-oxygenase) inhibitor indometha-
cin and the TxA
 
2
 
/PGH
 
2 
 
receptor blocker SQ29548 re-
stored hypoxia–reoxygenation-impaired relaxation without
affecting 6-keto-PGF
 
1
 
a
 
 release (Fig. 1 A). This suggests that
a COX-derived product, TxA
 
2
 
 or PGH
 
2
 
, caused vasocon-
striction via the TxA
 
2
 
/PGH
 
2
 
 receptor (Fig. 1 A). A role of
TxA
 
2
 
 was excluded, as CGS13080, a TxA
 
2
 
 synthase inhib-
itor, did not affect hypoxia–reoxygenation-triggered vaso-
Figure 1. Hypoxia–reoxygen-
ation on angiotensin II–triggered
relaxation and eicosanoid metab-
olism in BCA. (A) Effects of
indomethacin, SQ 29548,
CGS13080, SOD, L-NMMA,
and L-NAME on angiotensin II–
triggered relaxation (white bars)
and the release of 6-keto-PGF1a
(black bars) and PGE2 (hatched
bars) in hypoxia–reoxygenated
BCA. After having obtained a
reference response to angiotensin
II, the coronary strip was ex-
posed to hypoxia for 40 min af-
ter 40-min reoxygenation in
presence of indomethacin (10 mM), CGS13080 (10 mM), SQ-29548 (10 mM), PEG-SOD (500 U/ml), L-NMMA (1024 M), or L-NAME (1024 M).
PGE2 and 6-keto-PGF1a in the media were analyzed by ELISA. Data represent means 6 SEM from 10 experiments. (B) Effects of superoxide, NO, and
concurrent administration of superoxide and NO on angiotensin II–induced vasorelaxation and prostaglandin release in BCA. After having obtained a
reference response to angiotensin II, the coronary strip was exposed to superoxide generated from 10 mU/ml xanthine oxidase/100 mM hypoxanthine or
to NO generated from 20 mM DEA-NO or superoxide plus NO. PGE2 (hatched bars) and 6-keto-PGF1a (black bars) in the media were analyzed by
ELISA. Data represent means 6 SEM from 12 experiments. White bars, relaxation. 
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spasm (Fig. 1 A), and the levels of TxB
 
2
 
 remained low and
unaffected after hypoxia–reoxygenation treatment (97 
 
6
 
11 vs. 99 
 
6
 
 15 pg/30 min). The level of 8-iso-PGF
 
2
 
a
 
, which
also could act on the TxA
 
2
 
/PGH
 
2
 
 receptor (14), was low
and remained unchanged after hypoxia–reoxygenation (43 
 
6
 
12 vs. 47 
 
6
 
 17 pg/30 min).
PGH
 
2
 
 is known to cause vasoconstriction via the TxA
 
2
 
/
PGH
 
2 receptor (13). In arterial vessels, PGI2 is metabo-
lized primarily by PGI2 synthase to yield PGI2. Therefore,
we postulated that an inhibition on PGI2 synthase could
be the primary cause for the accumulation of PGH2, which
then caused vasoconstriction by stimulating the TxA2/PGH2
receptor. Parallel measurements of prostaglandins in the in-
cubation medium further supported this hypothesis. Hy-
poxia–reoxygenation lowered 6-keto-PGF1a formation but
raised the level of PGE2, an enzymatic or nonenzymatic
metabolite of PGH2 (Fig. 1 A). As COX activity was slightly
decreased after hypoxia–reoxygenation, an excess formation
of PGH2 after hypoxia–reoxygenation could be excluded.
Conclusive evidence for an inactivation of PGI2 synthase
came from the experiments with 14C-PGH2 as a substrate for
PGI2 synthase. A significant inhibition on the conversion of
14C-PGH2 into 6-keto-PGF1a (289 6 8%) with a con-
comitant increase of PGE2 (135 6 21%) was observed, con-
firming the selective inhibition of PGI2 synthase and the
reorientation of PGH2 metabolism toward PGE2 after hy-
poxia–reoxygenation.
The sustained vasoconstriction after hypoxia–reoxygen-
ation could also have been the consequence of a decreased
sensitivity of vascular smooth muscle to NO. However,
NO generated from DEA-NO in arteries with or without
hypoxia–reoxygenation resulted in a similar potency to in-
duce vasorelaxation. Similarly, an increased sensitivity of
the TxA2/PGH2 receptor was excluded, as pD2 (the nega-
tive logarithm of the molar concentration of agonist that
elicits a half- maximal response) of U46619, an agonist for
the TxA2/PGH2 receptor, was identical before and after
exposure to hypoxia–reoxygenation (7.7 6 0.5 vs. 7.8 6
0.5). A correspondent dose of PGE2 (20 ng/ml) applied to
the bath solution did not cause vasoconstriction (data not
shown), indicating that the higher levels of PGE2 after hy-
poxia–reoxygenation were not responsible for the second
constriction phase.
According to our working hypothesis, hypoxia–reoxy-
genation could induce peroxynitrite formation, which in-
activates PGI2 synthase. To test whether peroxynitrite was
indeed responsible for the hypoxia–reoxygenation-induced
vasospasm, the NO synthase inhibitors, both L-NMMA
(1024 M) and L-NAME (1024 M) were concurrently admin-
istered during hypoxia–reoxygenation. L-NMMA, which
reduced the angiotensin II–induced relaxation phase by
about 25% without affecting 6-keto-PGF1a formation in
normal vessels (data not shown), prevented hypoxia–reoxy-
genation-induced suppression of angiotensin II–induced va-
sorelaxation and 6-keto-PGF1a release (Fig. 1 A); L-NAME
was as effective as L-NMMA (data not shown).
Alternatively, concurrent administration of PEG-SOD
(500 U/ml) abolished hypoxia–reoxygenation-induced sec-
ondary vasoconstriction and restored angiotensin II–stimu-
lated vasorelaxation by blunting the hypoxia–reoxygenation-
mediated inhibition on 6-keto-PGF1a formation (Fig. 1 A).
It was important to show that neither NO nor O2
.2
alone could cause vascular dysfunction and inhibition on
Figure 2. Immunohistochemical colocalization of a polyclonal anti–
PGI2 synthase Ab and an mAb against 3-nitrotyrosine in hypoxia-reoxy-
genated BCA. The yellow coloring resulting from a computer-generated
overlay of green (3-nitrotyrosine) and red (PGI2 synthase) fluorescence
indicates areas of the colocalization of antinitrotyrosine and anti–PGI2
synthase Abs in BCA with or without hypoxia–reoxygenation treatment.
All pictures were obtained under 400-fold magnification with identical
camera and print settings. (A) 3-nitrotyrosine staining in a sham-treated
artery (green), where 3-nitrotyrosine staining is very weak and the endo-
thelium is intact. The green wiggly line is due to endogenous fluores-
cence of the lamina and not specific immunostaining for 3-nitrotyrosine.
(B) 3-nitrotyrosine staining in a hypoxia-reoxygenated artery; both en-
dothelium and vascular smooth muscle cells are strongly immunopositive
for 3-nitrotyrosine (green). (C) The staining of PGI2 synthase Ab in a hy-
poxia-reoxygenated artery. Dense staining with anti–PGI2 synthase Ab
was visible in both endothelium and smooth muscle (red). (D) A com-
puter-generated overlay of the stainings with the Abs against 3-nitroty-
rosine (B) and PGI2 synthase (C) in a hypoxia-reoxygenated artery. Yel-
low indicates the colocalization of the binding with both Abs. (E) An
hypoxia-reoxygenated artery was stained for antinitrotyrosine Ab in the
presence of 10 mM free 3-nitrotyrosine. Only the autofluorescence of the
lamina is visible. (F) 3-nitrotyrosine stainings in a hypoxia-reoxygenated
artery in the presence of L-NMMA, where the staining for 3-nitroty-
rosine is only weakly visible in both endothelium and vascular smooth
muscle. (G) 3-nitrotyrosine stainings in a hypoxia-reoxygenated artery in
the presence of PEG-SOD, where 3-nitrotyrosine staining is weakly visi-
ble in vascular smooth muscle. (H) An hypoxia-reoxygenated artery was
stained for 3-nitrotyrosine when the Ab against 3-nitrotyrosine was omit-
ted, where only the autofluorescence of the lamina is visible.138 Hypoxia–Reoxygenation Causes Nitration of Prostacyclin Synthase
PGI2 release. Therefore, preincubation of BCA with an
O2
.2-generating system (10 mU/ml xanthine oxidase/100
mM hypoxanthine) did not significantly affect either angio-
tensin II–triggered vasorelaxation or 6-keto-PGF1a release
(Fig. 1 B). Alternatively, the incubation of BCA with
DEA-NO (20 mM) as an NO-releasing system also failed
to affect angiotensin II–induced relaxation and 6-keto-
PGF1a release (Fig. 1 B). However, concomitant adminis-
tration to the organ baths of both O2
.2- and NO-generat-
ing agents for 40 min caused a loss of PGI2-dependent
vasorelaxation, an indomethacin- and SQ29548-sensitive
vasospasm, and a nitration of PGH2 synthase (Fig. 1 B).
As previously described, the exposure of BCA to perox-
ynitrite produced a nitrated protein that colocalized with
PGI2 synthase (9). The same technique was applied to hy-
poxia–reoxygenation-exposed BCA segments after their
mechanical responses had been established. Staining with
antinitrotyrosine Ab was weakly visible in control tissue
(Fig. 2 A), but clearly enhanced stainings emerged in endo-
thelium and smooth muscle after hypoxia–reoxygenation
(Fig. 2 B), where the stainings with Ab against PGI2 syn-
thase were intensively presented (Fig. 1 C). A computer-
generated overlay of the stainings with antinitrotyrosine
(green) and anti–PGI2 synthase (red) resulted in the yellow
colocalizing patches in vessels after hypoxia–reoxygenation
(Fig. 2 D). The presence of L-NMMA or PEG-SOD abol-
ished the increased stainings with antinitrotyrosine Ab (Fig. 2,
F and G) but not those with anti–PGI2 synthase Ab (data
not shown). The specificity of the staining with antinitro-
tyrosine Ab was deduced from its suppression by 10 mM
3-nitrotyrosine (Fig. 2 E) and the lack of staining when an-
tinitrotyrosine Ab was omitted (Fig. 2 H). 3-chloro- or
3-aminotyrosine or phosphotyrosine were ineffective in
blocking the stainings with antinitrotyrosine Ab (data not
shown).
Further evidence for hypoxia–reoxygenation-triggered ty-
rosine nitration of PGI2 synthase came from the immunopre-
cipitation with both antibodies against 3-nitrotyrosine and
PGI2 synthase. Immunoprecipitation with anti–PGI2 syn-
thase Ab yielded similar amounts of protein in both hypoxia–
reoxygenation-treated arteries and control tissues (Fig. 3 A).
In Western blot analysis, a dense band was detected by anti-
nitrotyrosine Ab in the immunoprecipitates with anti–PGI2
synthase Ab from hypoxia–reoxygenation-treated vessel
homogenates against a weakly visible signal in those from
the control tissues (Fig. 3 A). In the same homogenates,
3-nitrotyrosine–containing proteins were precipitated with
antinitrotyrosine Ab in parallel. Higher amounts of these pro-
teins were recovered in hypoxia–reoxygenation-treated arter-
ies than in those without hypoxia–reoxygenation. Moreover,
when these precipitates were blotted and probed with anti–
PGI2 synthase Ab, a dense staining appeared in arteries with
hypoxia–reoxygenation (Fig. 3 B). In agreement with the im-
munohistochemistry results, both PEG-SOD and L-NMMA
effectively abolished the increased stainings with both anti-
bodies in the immunoprecipitates with either antinitrotyro-
sine or anti–PGI2 synthase (Fig. 3, A and B).
In summary, our results indicate that hypoxia–reoxygen-
ation elicits the formation of O2
.2, which neutralize NO to
form peroxynitrite. Subsequently, peroxynitrite nitrates and
inactivates PGI2 synthase, leaving PGH2 unmetabolized,
which then causes vasospasm and platelet aggregation via
the TxA2/PGH2 receptor. This finding might offer a new
mechanism for coronary vasospasm during hypoxia–reoxy-
genation, especially in atherosclerotic arteries where PGI2
synthase is partially nitrated (15).
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Figure 3. Immunoprecipitation of nitrated pro-
teins and PGI2 synthase in hypoxia-reoxygenated
BCA. (A) Proteins from normal or hypoxia-reox-
ygenated BCA were immunoprecipitated with a
polyclonal Ab against PGI2 synthase (a-PGI2 syn-
thase) after hypoxia–reoxygenation. As described
in Materials and Methods, proteins precipitated by
a-PGI2 synthase were separated electrophoreti-
cally and immunostained with a monoclonal a-PGI2 synthase (left) or a monoclonal a-nitrotyrosine (right). Lane A, hypoxia–reoxygenation 1 L-NMMA;
lane B, hypoxia–reoxygenation 1 SOD; lane C, hypoxia–reoxygenation; lane D, control. (B) 3-nitrotyrosine–positive proteins were precipitated by an mAb
against 3-nitrotyrosine. Proteins were separated similarly and analyzed by immunoblots with polyclonal Ab against PGI2 synthase. Lane A, control; lane B,
hypoxia–reoxygenation; lane C, hypoxia–reoxygenation 1 L-NMMA; lane D, hypoxia–reoxygenation 1 SOD.139 Zou and Bachschmid Brief Definitive Report
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